Dedicated to making life better for people suffering from rare diseases with few or no treatment options

Leveraging our proprietary, autologous fibroblast technology platform to create personalized therapies for localized treatments targeting the underlying cause of disease

Expanding our in-house cGMP operation to support a robust pipeline of innovative cell-based gene therapies

We are focused on developing disease-modifying therapies that address unmet medical needs of patients and families suffering from rare diseases with the goal of making a positive difference in their lives.

Matthew Gantz, President and Chief Executive Officer

Our robust development pipeline of personalized, targeted and redosable therapies

Leveraging our proprietary, autologous fibroblast technology platform

What's New

Press Release
Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available

Read More
Media Coverage
U.S. Food and Drug Administration Bulletin

FDA Awards 11 Grants to Clinical Trials to Develop New Medical Products for Rare Disease Treatments

Read More
Press Release
Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments

Read More
Press Release
Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer

Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial

Read More